Lateral Flow Assays (LFAs) are a widely used diagnostic test format - used in COVID rapid tests and home pregnancy tests, for example. Unfortunately, traditional LFAs are not sensitive enough for many applications and only provide a positive or negative result.
At Afimacheck, we are developing a robust technology for reading lateral flow assays that greatly enhances sensitivity. Our reader is capable of working with most commercial LFAs to enhance results and open the door to new testing opportunities.
Enhances the sensitivity of existing inexpensive lateral flow assays. Able to detect THC in oral fluids at 2ng/ml.
Patented technology that takes less than a minute for analysis. Approximately 15 minutes from collection to results.
Replaces the need for interpretation of visual lines with direct numerical results.
The AfimaCheck Reader empowers workplace drug testing enabling zero-tolerance cannabis policies. Our technology is able to detect and quantify the presence of cannabis in oral fluid at concentrations as low as 2ng/ml.
Our patented thermophotonic lock-in technology allows quantitative measurements of existing Lateral Flow Assays. We are unlocking unprecedented detection sensitivity in low-cost paper-based testing.
ON-SITE ORAL FLUID TESTING FOR CANNABIS USE
DETECTION OF SARS-COVID2 WITHIN 6 DAYS OF INFECTION
ONSITE DETECTION OF HERD HEALTH AND AFLOTOXIN
POINT-OF-NEED DEVICES FOR FOODBORNE PATHOGEN SCREENING.
EARLY SCREENING FOR NONCOMMUNICABLE DISEASE.
RAPID TESTING FOR THC IN ORAL FLUIDS AT THE LEGAL LIMITS